http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TR-201718258-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97110cfedc7d4e881b9d01843a26d3d2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b557a92af6717c2f152b1a2d9cadf4e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a174cd5e05d3536436de666da8d8081d |
| publicationDate | 2019-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TR-201718258-A2 |
| titleOfInvention | New strategies developed for the treatment of tamoxifen resistant breast cancer. |
| abstract | The invention relates to phosphodiesterase 4D (PDE4D) modulators that induce cyclic adenosine monophosphate (cAMP), which can be used in the treatment of breast cancer and particularly in patients who develop resistance to tamoxifen. |
| priorityDate | 2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.